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Phenotypic expression of primary hyperoxaluria: Comparative The primary hyperoxalurias are inborn errors of me-
features of types I and II. tabolism that result from specific hepatic enzyme defi-
Background. The primary hyperoxalurias are autosomal re- ciencies [1]. In type I primary hyperoxaluria (PHI), defi-
cessive disorders resulting from deficiency of hepatic alanine:gly-
ciency and/or mistargeting of hepatic alanine:glyoxylateoxylate aminotransferase (PHI) or d-glycerate dehydrogenase/
aminotransferase results in metabolic overproduction ofglyoxylate reductase (PHII). Marked hyperoxaluria results in
oxalate and glycolate [2]. In type II primary hyperoxaluriaurolithiasis, renal failure, and systemic oxalosis. A direct compar-
ison of PHI and PHII has not previously been available. (PHII), deficiency of d-glycerate dehydrogenase/glyoxy-
Methods. Twelve patients with PHI and eight patients with late reductase results in metabolic overproduction of oxa-
PHII with an initial creatinine clearance of greater than or late and glycerate [3]. In both PHI and PHII, the excessequal to 50 mL/min/1.73 m2 underwent similar laboratory eval-
oxalate is excreted in the urine but is of low solubilityuation, clinical management, and follow-up. Diagnosis of PHI
and precipitates as a calcium salt. High urinary oxalateand PHII was made by hepatic enzyme analysis (N 5 11),
increased urinary excretion of glycolate or glycerate (N 5 7), concentrations result in urolithiasis. Over time, renal
or complete pyridoxine responsiveness (N 5 2). Six PHI and parenchymal damage caused by calcium oxalate deposi-
five PHII patients had measurements of calcium oxalate crys- tion leads to renal insufficiency, hyperoxalemia, and sys-
talluria, urine supersaturation, and urine inhibition of calcium temic deposition of calcium oxalate. End-stage renal fail-oxalate crystal formation.
ure, metabolic bone disease, erythropoietin refractoryResults. PHI and PHII did not differ in age at the onset of
anemia, skin ulcers, digital gangrene, cardiac arrhyth-symptoms, initial serum creatinine, or plasma oxalate concen-
tration. Urine oxalate excretion rates were higher in PHI (2.19 6 mias, and cardiomyopathy reflect systemic oxalate depo-
0.61 mmol/1.73 m2/24 hours) than PHII (1.61 6 0.43, P 5 0.04). sition. Survival is poor with maintenance dialysis and in
Urine osmolality, calcium, citrate, and magnesium concentra- patients with extensive tissue oxalosis. Treatment strate-
tions were lower in PHI than PHII (P 5 0.001, P 5 0.019, P 5 gies include pharmacologic doses of pyridoxine for pa-0.0002, P 5 0.03, respectively). Crystalluria scores and calcium
tients with PHI responsive to this cofactor of alanine:gly-oxalate inhibitory activity of the urine did not differ between
oxylate aminotransferase and the use of agents such asPHI and PHII. Calcium oxalate supersaturation in the urine
was less in PHI (7.3 6 1.9) compared with PHII (14.0 6 3.3, orthophosphate and citrate, which reduce calcium oxa-
P 5 0.002). During follow-up of 10.3 6 9.6 years in PHI and late crystallization in the urine and in the renal paren-
18.1 6 5.6 years in PHII, stone-forming activity and stone proce- chyma [4–6]. For patients with end-stage renal disease,
dures were more frequent in PHI than PHII (P , 0.01 and kidney transplantation or combined kidney and liverP 5 0.01, respectively). Four of 12 PHI compared with 0 of 8
transplantation has been successful [7, 8].PHII patients progressed to end-stage renal disease (P 5 0.03).
Type I primary hyperoxaluria (McKusick 259900) andConclusion. The severity of disease expression is greater in
type I primary hyperoxaluria than in type II. The difference PHII (McKusick 260000) are rare, autosomal recessive
may be due to greater oxalate excretion and lower concentra- disorders. Recent studies suggest a prevalence of PHI
tions of urine citrate and magnesium in patients with PHI in France of 1.05/million population with an incidence
compared with PHII. rate of 0.12 per million per year [9]. As of 1997 [10, 11],
only 24 patients with PHII had been described in the
world literature, 8 of whom were identified during evalu-
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ation of an extensive Canadian pedigree [12]. Seventeenaminotransferase, d-glycerate dehydrogenase/glyoxylate reductase,
plasma oxalate, crystalluria, calcium oxalate, stone forming activity. of the 24 patients had urolithiasis, and 1 had nephrocal-
cinosis [13]. Normal renal function was noted in sevenReceived for publication January 24, 2000
of the patients, reduced renal function in one, and end-and in revised form May 17, 2000
Accepted for publication August 4, 2000 stage renal disease in three [11, 14–17]. Renal function
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of the 24 patients had follow-up information available seven of the PHII patients because they were cared for
as presumed PHI before PHII was described or prior to[11, 13, 15, 16]. It has been suggested that patients with
PHII may have milder disease expression when com- clinical availability of urine glycerate determinations and
hepatic enzyme analysis. None of the PHII patientspared with PHI [11, 18], although not all authors agree
[19]. Both PHI and PHII are characterized by marked showed a significant reduction in urine oxalate following
treatment with pyridoxine.hyperoxaluria. Reasons for the apparent difference in
clinical outcome have not been elucidated. Stone-forming activity was defined as an increase in
the number of stones or increase in size of stones asAt the Mayo Clinic, we have identified 12 patients with
PHI and 8 patients with PHII who underwent similar compared with the previous visit, determined by abdomi-
nal radiography with renal tomography. Because of visitsdiagnostic evaluation and consistent medical manage-
ment with similar duration of follow-up. Information when radiographs were not obtained, stone-forming ac-
tivity was not able to be determined in 11 out of 95from these two groups permits understanding of the dif-
ferences and of the similarities in the clinical and in (12%) of PHI visits and 19 out of 115 (16.5%) of PHII
visits.the laboratory expression of these subtypes of primary
hyperoxaluria. This report provides the first direct data From 1980 to 1988, urinary oxalate was measured by
the method of Olthuis et al [20] [normal reference rangecomparing patients with PHI and PHII.
20 to 60 mg (0.23 to 0.68 mmol)/24 h] and after 1988 by
the immobilized oxalate oxidase method [normal refer-
METHODS
ence range 10 to 40.5 mg (0.11 to 0.46 mmol)/day] [21].
Medical records of all patients with primary hyperoxa- Urine samples were collected for 24 hours into contain-
luria seen at the Mayo Clinic from 1966 to 1995 were ers with concentrated hydrochloric acid to prevent oxa-
reviewed by the authors. Of the 28 patients with a defini- late crystallization and to prevent ascorbate conversion
tive diagnosis of PHI or PHII, 8 patients who presented to oxalate. All urine oxalate values are expressed as
with end-stage renal disease are not included in this mmol/1.73 m2/24 hours to provide valid comparisons be-
report. All eight of these excluded patients had PHI by tween children and adults [22]. Urine glycolate and
hepatic enzyme analysis. Twelve PHI patients and seven l-glyceric acid were measured by gas chromatography
PHII patients presented for initial evaluation with good [23]. The normal reference range for glycolate was 14
renal function, defined as a creatinine clearance of to 114 mg/mg creatinine (21 to 168 mmol/mmol creati-
greater than or equal to 50 mL/min/1.73 m2. One PHII nine). The normal reference range for l-glyceric acid
patient was studied one year after kidney only trans- was 22 to 185 mg/mg creatinine (24 to 198 mmol/mmol
plantation when her serum creatinine was 0.9 mg/dL. The creatinine). Enzyme studies of liver tissue were per-
20 patients who underwent similar diagnostic evaluation, formed in the laboratories of Drs. C. Danpure and G.
clinical management, and follow-up are the subjects of Rumsby [19, 24].
this report. All patients were cared for by one of the Eleven patients (6 with PHI and 5 with PHII) had
authors. Partial information regarding some of the patients measurements of calcium oxalate crystalluria, calcium
has been included in previous publications [4, 11, 18]. oxalate supersaturation in urine, and inhibition of cal-
Of the 12 patients with PHI, 6 were confirmed by cium oxalate crystal formation in urine. These studies
hepatic enzyme analysis of the patient (3 patients) or an were obtained when the patients were not receiving med-
affected sibling (3 patients) to have alanine:glyoxylate ications. After obtaining informed consent, patients were
aminotransferase (AGT) deficiency. Four patients were admitted to the General Clinical Research Center for
confirmed by increased urine glycolate and two patients three days while on their normal fluid intake and normal
by complete pyridoxine responsiveness. Of the eight pa- diet. Reference values were obtained in 16 normal sub-
tients with PHII, five patients from two unrelated families jects [7 women and 9 men; median age 31 years (range
were confirmed by hepatic enzyme analysis of the patient 17 to 39 years)] who were unrelated to the patients. Two
(2 patients) or an affected sibling (3 patients) to have consecutive 24-hour urine collections were obtained.
deficiency of glyoxylate reductase or d-glycerate dehy- Each voiding was collected in a beaker kept at 378C.
drogenase. The remaining three patients had high urine The volume and pH of each sample were measured. A
glycerate concentrations and normal glycolate. 2 mL aliquot of each voiding was filtered immediately
For management of hyperoxaluria and stone disease, by vacuum through a 0.22 mm Nucleopore filter (25 mm
patients were instructed to drink eight ounces (a glass) diameter). The filter was then rinsed with four drops of
of water every hour while awake and when up to void distilled water to remove traces of soluble salts and was
during the night. Their usual diet was not changed. Six- air dried for crystal determination. Ten percent of each
teen patients received both neutral phosphate and pyri- urine voiding was placed under mineral oil for measure-
doxine. Two patients received neutral phosphate alone ment of carbon dioxide, and 10% was stored with addi-
tion of 6N hydrochloric acid and the remainder in a pool.and two pyridoxine alone. Pyridoxine was prescribed to
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Table 1. Clinical and laboratory characteristicsEach of these aliquots was stored at 48C until completion
of the 24-hour collection. Measurements were then made Type I Type II
N 5 12 N 5 8 Pimmediately, or the fractions were frozen. These 24-hour
Age onset symptoms years 10.269.8 13.567.8 0.46pooled collections were analyzed for the major ionic
Age at diagnosis years 16.6613.4 17.9612.9 0.82species (Na, K, Ca, Mg, NH4, citrate, sulfur, phosphorus, Serum creatinine baseline mg/dL 0.960.2 0.860.2 0.18
carbon dioxide, chloride, oxalate, and uric acid). Osmol- CCr baseline mL/min/1.73 m2 92624 121631 0.04
Uoxalate mmol/1.73 m2/24 ha 2.1960.61 1.6160.43 0.04ality was analyzed by freeze point osmometry; sodium
Plasma oxalate lmol/Lb 5.763.5 3.863.4 0.34and potassium by flame emission spectrophotometry;
Fractional excretion oxalatec 3.4160.69 2.7661.63 0.36
creatinine and phosphorus by Auto Analyzer; chloride Urine glycolate lg/mg creatinined 1806148 48640 0.06
Urine glycerate lg/mg creatininee 22664 112461354 0.04by coulometric titration; uric acid enzymatically with
uricase; calcium and magnesium by atomic absorption; Values are mean 6 SD.
a Normal urinary oxalate ,0.46 mmol/24 hourssulfate by a modification of the gravimetric method [25];
b Normal plasma oxalate 0.5 to 3.0 mmol/L
oxalate by the method of Olthuis et al [20]; citrate by c Normal FEoxalate 0.47 6 0.3
d Normal urinary glycolate #114the method of Natelson, Pincus, and Lugovoy [26]; am-
e Normal urinary glycerate #185
monium ion by the Berthelot technique; and carbon di-
oxide content by microgasometer. Crystalluria was as-
sesed by the method of Werness using petrographic
microscopy and scanning electron microscopy with en-
ergy dispersive x-ray spectroscopy [27]. Twenty-four–
hour pooled collections were analyzed with a seeded
crystal growth system to determine whether formation
of calcium oxalate crystals was inhibited [28]. In this
system, one inhibitor unit was defined arbitrarily as the
concentration of inhibitor required for 50% reduction in
the rate of crystal growth (k/k 2 kA 5 2) under standard
conditions. Ionic strength, free ion activity, and supersat-
uration with calcium oxalate were estimated using
Fig. 1. Urine oxalate in patients with primary hyperoxaluria types IEQUIL 2 [29]. The results from the two 24-hour collec-
(PHI; s) and II (PHII; d), P 5 0.04. The shaded area denotes a normaltions were averaged.
range of ,0.46 mmol (40.5 mg).
Statistical analysis was by t-test for continuous vari-
ables and by chi square for nominal variables. Spearman
correlation coefficients were used to compare the rates
PHI than PHII, although the difference did not reachof decline in renal function. Kaplan–Meier survival per-
statistical significance. The urinary concentrations of ci-centages were used to compare the numbers of patients
trate, calcium, and magnesium were lower in patients withprogressing to end-stage renal disease during follow-up.
PHI compared with those with PHII (P 5 0.0002, P 5
0.019, and P 5 0.03, respectively). Urinary concentrations
RESULTS of pyrophosphate, while lower in PH patients than normal
Of the PHI patients, six were male, and six were fe- subjects, did not differ between PHI and PHII. Calcium
male. Among the PHII patients, one was male, and seven oxalate supersaturation of 7.3 6 1.9 in PHI and 14.0 6
were female. The 12 patients with PHI were from 10 3.3 in PHII was higher than the 2.5 6 0.6 observed in
unrelated families, and the 8 patients with PHII were control subjects (PHI vs. control P 5 0.04, PHII vs. control
from 4 unrelated families. Initial clinical and laboratory P 5 , 0.001). Calcium oxalate supersaturation was greater
characteristics are displayed in Table 1. No differences in PHII than PHI (P 5 0.002; Table 2). Crystal scores
were found between PHI and PHII with regard to age were greater in PHI (2.7 6 1.4) and PHII (2.4 6 0.5)
at onset of symptoms, age at diagnosis, nor initial serum compared with control subjects 0.6 6 0.7 (PHI vs. control
creatinine. Twenty-four–hour creatinine clearance at ini- P 5 0.001, PHII vs. control P 5 0.00001), but did not
tial assessment, while excellent in both groups, was lower differ between the PH subtypes. Calcium oxalate inhibi-
in PHI as compared with PHII (P 5 0.04). There was tion was significantly reduced in both PHI at 23.8 6 13.7
no difference between groups in plasma oxalate concen- and PHII at 29.8 6 5.2 compared with control subjects
trations nor fractional excretion of oxalate. 97 6 36 (PHI vs. control P 5 0.0001, PHII vs. control
Urine oxalate excretion rates were higher in PHI than P 5 0.0002), but not different between subtypes.
PHII (P 5 0.04; Fig. 1). Urine findings are shown in Table In the PHI and PHII groups combined, the 24-hour
2. Urine oxalate concentrations did not differ between urine oxalate excretion rate correlated inversely with
the initial creatinine clearance (P 5 0.01). Urine citrategroups (P 5 0.41). Mean urine volume was higher in
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Table 2. Urine findings
Type I Type II Normal subjects
N 5 6 N 5 5 P a N 5 16
Urine pH 5.660.3 5.860.5 0.21 6.260.3
Volume mL/24 h 21936818 16516601 0.15 19256519
UOsm mOsm/kg 302698 499658 0.001 5606212
Ionic strength 0.08060.013 0.15560.021 0.001 0.15060.045
U[ox] mg/dL 8.365.8 10.866.8 0.42 2.161.0
U[Ca] mg/dL 2.861.7 7.065.2 0.02 8.863.6
U[Citrate] mg/dL 8.064.4 47.7624.8 0.0002 38.4619.2
U[Mg] mg/dL 4.462.5 7.561.6 0.03 9.063.6
U[P2O7] mg/dL 0.0560.03 0.1760.16 0.11 0.4260.17
CaOx SS 7.361.9 14.063.3 0.002 2.560.6
Crystal score 2.761.4 2.360.5 0.62 0.660.7
CaOx inhibition 23.8613.7 29.865.2 0.38 97636
a Type I compared with type II
Table 3. Primary hyperoxaluria outcomeexcretion, expressed as mg/g creatinine was 236 6 130
in PHI and 787 6 432 in PHII (P 5 0.002) and also Type I Type II
N 5 12 N 5 8 Pcorrelated with initial renal clearance (P 5 0.02).
Duration follow-up years 10.369.6 18.165.6 0.05During mean follow-up of 10.3 years in PHI and 18.1
Patients with stones 12/12 7/8 0.21years in PHII (Table 3), stone-forming activity was found
Stone-forming activitya
in 37% of evaluable visits in PHI and in 7% of evaluable (proportion of visits) 0.37 (31/84) 0.07 (7/96) ,0.01
Stone procedures per patient 2.961.6 1.060.9 0.01visits in PHII (P , 0.01). Surgical intervention for urolithi-
Change in renal clearanceasis was required more often in PHI than PHII (P 5 0.016). mL/min/1.73 m2/year 21.65c 21.04c 0.39
Four of the 12 patients with PHI developed end-stage renal ESRD during follow-up 4/12 0/8 0.03
Renal clearanceb mL/min/1.73 m2 95639 110614 0.44disease during the course of follow-up. One PHII patient
a Stone-forming activity is defined as an increase in number of stones or sizepresented initially with renal failure but maintained a
of stones demonstrated by renal imaging studies when compared with the previ-
renal allograft iothalamate clearance of 83 mL/min/ ous visit
b Kidney function at last follow-up in patients not requiring dialysis (type I,1.73 m2 at 20 years following renal transplantation de-
N 5 8 patients; type II, N 5 8 patients one of whom was studied with a functioning
spite persistent hyperoxaluria on treatment with neutral renal allograft)
c Medianphosphate. Of the eight patients with PHI and eight
patients with PHII who had preserved renal function at
last follow-up, renal clearance was similar with mean
values of 95 and 110 mL/min/1.73 m2, respectively (P 5 who presented with end-stage renal disease as well as
0.44). by patients reported in the literature [14–16, 30].
The explanation for more active stone formation and
greater renal parenchymal damage in PHI comparedDISCUSSION
with PHII is suggested by the greater oxalate excretion
Patients with PHI and PHII have increased urinary rates observed in PHI as well as by differences in urine
calcium oxalate supersaturation, increased calcium oxa- composition. Oxalate excretion rates were inversely cor-
late crystalluria, and decreased urine inhibition of cal- related with renal clearance at initial evaluation (P 5
cium oxalate crystal formation when compared with nor- 0.01). In cell culture systems and in animal models,
mal subjects, and they demonstrate a life-long propensity hyperoxaluria causes injury to renal tubular epithelial
for urolithiasis. Our data confirm that patients with PHII cells, inducing proliferation and cell disruption [31–33].
have a more favorable long-term clinical course than The interaction of calcium oxalate monohydrate crystals
those with PHI. This difference was evident with regard and renal epithelial cells results in induction of genes
to metabolic stone-forming activity, number of surgical encoding plasminogen activator inhibitor and platelet-
interventions required for management of urolithiasis, derived growth factor (abstract; Hammes et al, J Am Soc
and preservation of renal function. These differences Nephrol 5:864A, 1994), suggesting a pathophysiologic
occurred despite a common management approach for mechanism for renal interstitial fibrosis in hyperoxaluric
all patients with primary hyperoxaluria included in this states. Calcium oxalate crystals also can be demonstrated
report. Although PHII appears less severe, the potential in renal interstitium [31, 33]. In humans, interstitial in-
for end-stage renal disease and systemic oxalate deposi- flammation and interstitial fibrosis are reported in hyper-
oxaluria [34–37].tion remains. This possibility was reflected by our patient
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When compared with PHII, the PHI group had lower vation studies were not performed in the patients and
concentrations of urinary citrate and magnesium. Both would be needed to address this observation further. It
citrate and magnesium form complexes in urine, citrate is also possible that PHI patients, who had more frequent
with calcium and magnesium with oxalate, reducing the symptomatic stone episodes, were more conscientious
amount of oxalate and calcium available for precipitation regarding maintenance of a large oral fluid intake.
[28]. Citrate also inhibits calcium oxalate crystal forma-
tion [28]. Whether the low concentrations of these inhibi-
CONCLUSIONtors in PHI result from metabolic differences is not clear
Clinical characteristics such as age at onset of symp-from these studies. However, our observations in other
toms and age of diagnosis are not helpful in differentiat-PHI patients of persistently low urine citrate concentra-
ing PHI from PHII. Furthermore, while there are differ-tions during periods of continued high urinary oxalate
ences with regard to urine oxalate excretion rates andexcretion following successful hepatic transplantation
other urinary parameters, the overlap is such that these(unpublished data) suggest that the hypocitric aciduria
values are not sufficient in an individual patient to differ-is not a result of the hepatic enzyme abnormality in PHI.
entiate between PHI and PHII. Urinary glycolate andAdsorption onto crystal surfaces as the cause of hypocit-
glycerate values and hepatic enzyme analysis are neces-ric aciduria is supported by our previous observation
sary for accurate diagnosis. Advances in genetic testingthat calcium oxalate inhibitory activity in the urine of PH
may soon permit DNA analysis as an alternative [40, 41].patients returns to normal when crystalluria decreases or
The finding of eight patients with PHII from four unre-disappears with neutral phosphorus treatment [4].
lated families among our patients with primary hyperox-Reduced urine citrate concentrations and reduced ci-
aluria suggests that PHII may not be as rare as previouslytrate excretion could reflect renal tubulointerstitial in-
jury resulting from high urine oxalate concentrations or thought. Our observations confirm that PHII follows a
calcium oxalate crystals. Damage to renal tubular epithe- more benign long-term clinical course than PHI. Differ-
lium and interstitial inflammation have been reported in ences in metabolic production rates of oxalate and in
hyperoxaluric patients [34, 38, 39]. The observed correla- urinary chemical composition may account, in part, for
tion between urine citrate excretion and renal clearance this observation. Other factors remain to be evaluated.
(P 5 0.02) is consistent with this hypothesis.
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